Target intelligence / Profile preview

Arginyl-tRNA synthetase, cytoplasmic (ArgRS)

Target
ArgRS
Molecular classification
Enzyme, Aminoacyl-tRNA synthetase (Class I, subclass Ie)
01

Overview

Arginyl-tRNA synthetase, cytoplasmic (ArgRS) is an essential class I aminoacyl-tRNA synthetase enzyme responsible for the ligation of arginine to its cognate tRNA during cytoplasmic protein synthesis[1][4][7]. Encoded by the RARS1 gene, this homodimeric enzyme catalyzes the attachment of arginine to tRNA^Arg, a fundamental step in translation[1][4]. ArgRS exists in at least two cytoplasmic isoforms and is part of the multisynthetase complex with other aminoacyl-tRNA synthetases and accessory proteins[7][8]. Pathogenic loss-of-function bi-allelic variants in RARS1 cause a spectrum of human neurodevelopmental disorders, most notably a hypomyelinating leukodystrophy with variable severity, presenting as global developmental delay, epilepsy, and myelin defects in the central nervous system[5][7][8]. No direct small-molecule drugs are currently known to target ArgRS for therapeutic purposes, and its essentiality for translation makes it a challenging drug target.

Other names
RARS1RARSArginine--tRNA ligase, cytoplasmicarginyl-tRNA synthetasearginine tRNA ligase 1, cytoplasmicDALRD1HLD9
02

Biological functions

Catalysis of aminoacylation (charging) of tRNA with arginineEssential for cytoplasmic protein synthesisComponent of multisynthetase complex
03

Disease associations

Neurodevelopmental disorder (hypomyelinating leukodystrophy/Pelizaeus-Merzbacher-like disease)Developmental and epileptic encephalopathy
04

Safety considerations

Biallelic pathogenic variants can lead to early-onset neurodevelopmental disease, including severe hypomyelination, epilepsy, and developmental delay[7][5][8].

Beyond the preview

Go deeper on Arginyl-tRNA synthetase, cytoplasmic (ArgRS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arginyl-tRNA synthetase, cytoplasmic (ArgRS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call